Asymmetric sulfur ylide based enantioselective synthesis of D-*erythro*-sphingosine[†]

José Antonio Morales-Serna, Josep Llaveria, Yolanda Díaz, M. Isabel Matheu and Sergio Castillón*

Received 26th August 2008, Accepted 1st October 2008 First published as an Advance Article on the web 17th October 2008 DOI: 10.1039/b814882a

An asymmetric sulfur ylide reaction was employed to prepare an epoxide intermediate in a convergent manner. This epoxide was efficiently transformed into D-*erythro*-sphingosine.

Sphingolipids, named by Johann Ludwig Wilhelm Thudichum¹ in 1884 after the Greek Sphinx due to their enigmatic function, have emerged over the last several decades as a family of key signalling molecules, and include sphingosine **1**, ceramide **2**, and sphingosine-1-phosphate **3** (Fig. 1).² Data indicate that these lipids regulate fundamental and diverse cell processes such as differentiation, migration, and apoptosis.^{3,4} Moreover, on the organismal level, sphingolipids play roles in higher order physiological processes including inflammation⁵ and vasculogenesis.⁶ Recent studies implicate sphingolipid involvement in many of the most common human diseases including diabetes,⁷ cancers,⁸ infection by microorganisms,⁹ Alzheimer's disease,¹⁰ heart disease and an array of neurological syndromes.¹¹



Fig. 1 Naturally occurring sphingolipids.

The basic structure of a sphingolipid consists of a long-chain sphingoid base backbone linked to a fatty acid *via* an amide bond with the 2-amino group and to a polar head group at the C-1 position *via* an ester bond. There are four sphingosine stereoisomers with a wide range of biological activities.^{12,13} The isomer D-*erythro* is the most common metabolite and has been meticulously studied. We have recently reported efficient glycosylation protocols of this

† Electronic supplementary information (ESI) available: Experimental details and characterization data of all the new compounds. See DOI: 10.1039/b814882a

compound and analogues in order to obtain glycosphingolipids.¹⁴ Since, pure sphingosine and its derivatives are available in a limited amount from natural sources, many methods for their synthesis have been developed by using amino acids, carbohydrates and other building blocks as the starting materials.^{15,16} However, most of the methods require multistep reactions that result in low total yields. The key to cost-effective and efficient synthesis is the choice of a proper starting material that requires minimal protectiondeprotection steps.

In the present study, we report a convenient and concise route for the synthesis of D-*erythro*-sphingosine 1. Based on the retrosynthetic analysis depicted in Scheme 1, compound 1 can be generated from the corresponding epoxide 4 via an intramolecular ring-opening to introduce the amino functionality at C-2. The selectivity of the intermolecular opening is controlled by the double bond and affords the 3-amino derivative. For synthesising epoxide 4 we envisaged an asymmetric reaction between a chiral sulfur ylide obtained from bromide 6 and aldehyde 5, which can incorporate the nucleophile (X) for epoxide opening in its structure.



Scheme 1 Retrosynthetic analysis of D-erythro-sphingosine.

The aldehyde **5** is readily prepared from the alcohol **7**. Lipophilic chain fragment **6** should be available from allyl bromide (**8**) and alkene **9** by means of cross-metathesis (CM) in order to introduce the required E-olefin moiety.

As shown in Scheme 2, the synthesis started with the protection of hydroxyaldehyde 7 as a carbamate, since it is appropriate for opening the epoxide in a subsequent step. Thus, aldehyde 10 for

Departamento de Química Analítica y Química Orgánica, Universitat Rovira i Virgili, C/Marcel.li Domingo s/n, 43007 Tarragona, Spain. E-mail: sergio. castillon@urv.net; Fax: +34 977 558446; Tel: +34 977 559556



Scheme 2 Protection of alcohol 7.

asymmetric sulfur ylide reaction was obtained in excellent yield by reaction of hydroxyaldehyde 7 and benzyl isocyanate (1.5 equiv) in the presence of Et_3N , employing Et_2O as the solvent.

The high E-selectivity and the functional tolerance are attractive features of cross-metathesis olefination in the synthesis of natural products.¹⁷ In a recent synthesis of the sphingosines and phytosphingosines, CM has been used as a carbon chain elongation strategy.¹⁸ Therefore, we reasoned that a cross metathesis reaction of allyl bromide 8 and alkene 9 in presence of Grubbs'19 catalyst will provide the intermediate 6^{20} with the correct configuration. Substrate 8 was stirred with 4 equiv of olefin 9 and 0.02 equiv of second generation Grubbs' catalyst (B) in CH₂Cl₂ for 8 h at reflux. The reaction proceeded smoothly, and the desired coupling product 6 was obtained in 97% yield with an E: Z selectivity of 52 : 1. The homocoupling product of 8 was not observed by ¹H NMR. In this case the use of Ti(OⁱPr)₄ or other additive was not necessary to obtain excellent results. A decrease in the selectivity $(E: Z \ 11: 1)$ and the yield (78%) was observed when the first generation Grubbs' catalyst (A) was employed under similar conditions (Scheme 3).



Scheme 3 Synthesis of 6 by cross-metathesis.

The key step is the synthesis of the epoxide **13** with control of the configuration of the stereogenic centers at C-2 and C-3 by using the stoichiometric sulfur ylide reaction, which is of particular interest because of the valuable synthetic intermediates that have been generated using this reaction.²¹ The sequence developed to prepare epoxide **13** is summarized in Scheme 4. Sulfide **11**²² was selected as chiral auxiliary in order to prepare the corresponding chiral sulfur ylide.²¹ Reaction of sulfide **11** (1 equiv) with allyl bromide **6** (1.2 equiv) in CH₂Cl₂ and in the presence of AgBF₄ (4 equiv) afforded the required sulfonium salt **12** in 80% yield.²³ Subsequent treatment of the salt **12** with EtP₂ base (1.1 equiv) and the aldehyde **10** (1.1 equiv) furnished the desired epoxide **13** in 60% yield. Crucial to the success of the reaction were conditions that favoured the formation of stabilized ylide **15** (Fig. 2), namely employing the EtP₂ base at -78 °C in CH₂Cl₂.

To complete the synthesis (Scheme 4),²⁴ epoxide 13 was converted to oxazolidinone 14 with complete regio- and stereoselec-



Scheme 4 Synthesis of D-erythro-sphingosine.



Fig. 2 Ylide intermediate.

tivity first by treatment with NaHMDS (1.5 equiv) at -15 °C in THF.²⁵ Then, removal of the benzyl group employing Li (excess) and EtNH₂/*t*-BuOH at -78 °C gave **14** in 90% yield over two steps.^{184,26} Finally, alkaline hydrolysis of oxazolidinone **14** with KOH at reflux for 2.5 h furnished D-*erythro*-sphingosine **1** in quantitative yield. Synthetic **1** gave mp 72–74 °C (lit^{18d} mp 72–75 °C), $[\alpha]_D$ –1.6 (*c* 0.9 in CHCl₃) (lit^{18d} $[\alpha]_D$ –1.6) (*c*1 in CHCl₃)). 400 MHz ¹H and 125 MHz ¹³C NMR spectroscopic data were consistent with data reported for the synthetic product. The match of optical rotation values indicate that the formation of the epoxide **13** was completely stereoselective.

In summary, D-*erythro*-sphingosine has been obtained in 42% overall isolated yield and high enantioselectivity by using an asymmetric sulfur ylide reaction between the sulfonium salt **12** and the aldehyde **10** as the key step.

Acknowledgements

The authors acknowledge the financial support of DGI CTQ2005-03124 (Ministerio de Educación y Ciencia, Spain). J. Llaveria and J. A. Morales-Serna thanks DURSI (Generalitat de Catalunya) and Fons Social Europeo for a fellowship.

Notes and references

- 1 J. L. W. Thudichum, A treatise on the Chemical Constitution of the Brain, Bailliere, Tindall and Cox, London, 1884.
- 2 M. Tani, M. Ito and Y. Igarashi, Cell. Signal., 2007, 19, 229-237.
- 3 J. Riethmüller, A. Riehle, H. Grassmé and E. Gulbins, *Biochim. Biophys. Acta*, 2006, **1758**, 2139–2147.
- 4 C. F. Snook, J. A. Jones and Y. A. Hannun, *Biochim. Biophys. Acta*, 2006, **1761**, 927–946.
- 5 M. El Alwani, B. X. Wu, L. M. Obeid and Y. A. Hannun, *Pharmacol. Ther.*, 2006, **112**, 171–183.
- 6 K. M. Argraves, B. A. Wilkerson, W. S. Argraves, P. A. Fleming, L. M. Obeid and C. J. Drake, *J. Biol. Chem.*, 2004, 279, 50580–50590.
- 7 S. A. Summers and D. H. Nelson, Diabetes, 2005, 54, 591-602.
- 8 D. E. Modrak, D. V. Gold and D. M. Goldenberg, *Mol. Cancer. Ther.*, 2006, **5**, 200–208.
- 9 L. J. Heung, Ch. Luberto and M. Del Poeta, *Infect. Immun.*, 2006, 74, 28–39.
- 10 S. Zhou, H. Zhou, P. J. Walian and B. K. Jap, *Biochemistry*, 2007, 46, 2553–2563.
- 11 T. Kolter and K. Sandhoff, Biochim. Biophys. Acta, 2006, 1758, 2057– 2079.
- 12 A. H. Jr. Merril, S. Nimkar, D. Menaldino, Y. A. Hannun, C. Loomis, R. M. Bell, S. R. Tyahi, J. D. Lambeth, V. L. Stevens, R. Hunter and D. C. Liotta, *Biochemistry*, 1989, **28**, 3138–3145.
- 13 C. W. Sachs, L. M. Ballas, S. W. Mascarella, A. R. Safa, A. H. Lewin, C. Loomis, F. I. Carroll, R. M. Bell and R. L. Fine, *Biochem. Pharmacol.*, 1996, 52, 603–612.
- 14 (a) J. A. Morales-Serna, O. Boutureira, Y. Díaz, M. I. Matheu and S. Castillón, Org. Biomol. Chem., 2008, 6, 443–445; (b) O. Boutureira, J. A. Morales-Serna, Y. Díaz, M. I. Matheu and S. Castillón, Eur. J. Org. Chem., 2008, 1851–1854; (c) J. A. Morales-Serna, Y. Díaz, M. I. Matheu and S. Castillón, Org. Biomol. Chem., 2008, 6, 3831–3836.
- 15 For reviews, see: (a) J. Liao, J. Tao, G. Lin and D. Liu, *Tetrahedron*, 2005, **61**, 4715–4733; (b) A. H. Jr. Merrill and Y. A. Hannun, *Methods Enzymol.*, 2000, **311**, 91–479; (c) P. M. Koskinen and A. M. P. Koskinen, *Synthesis*, 1998, 1075–1091.
- 16 For recent synthesis of sphingosines see: (a) E. Abraham, E. A. Brock, J. I. Candela-Lena, S. G. Davies, M. Georgiu, R. L. Nicholson, J. H. Perkins, P. M. Roberts, A. J. Russel, E. M. Sánchez-Fernández, P. M. Scott, A. A. D. Smith and J. E. Thomson, Org. Biomol. Chem., 2008, 6, 1655–1673; (b) Y. Niu, X. Cao and X. S. Ye, Helv. Chim. Acta, 2008, 91, 746–752; (c) S. Kim, N. Lee, S. Lee, T. Lee and Y. M. Lee, J. Org. Chem.,

2008, 73, 1179–1385; (d) J. Jeon, M. Shin, J. W. Yoo, J. S. Oh, J. G. Bae, S. H. Jung and Y. G. Kim, *Tetrahedron Lett*, 2007, 48, 1105–1108; (e) I. Kumar and C. V. Rode, *Tetrahedron: Asymmetry*, 2007, 18, 1975–1980; (f) H. J. Yoon, Y.-W. Kim, B. K. Lee, W. K. Lee, Y. Kim and H.-J. Ha, *Chem. Commun.*, 2007, 79–81; (g) D. Mormeneo, J. Casas, A. Llebaria and A. Delgado, *Org. Biomol. Chem.*, 2007, 5, 3769–3777; (h) H. Yang and L. S. Liebeskind, *Org. Lett.*, 2007, 9, 2993–2995; (i) D. Enders, J. Palecek and C. Grondal, *Chem. Commun.*, 2006, 655–657; (j) S. Kim, S. Lee, T. Lee, H. Ko and D. Kim, *J. Org. Chem.*, 2006, 71, 8661–8664; (k) Y. Cai, C.-C. Ling and D. R. Bundle, *Org. Biomol. Chem.*, 2006, 4, 1140–1146; (l) W. Desadee and T. Ishikawa, *J. Org. Chem.*, 2005, 70, 9399–9406.

- 17 For review, see: (a) R. W. Franck and M. Tsuji, Acc. Chem. Res., 2006, 39, 692–701; (b) J. Prunet, Curr. Top. Med. Chem., 2005, 5, 1559–1577; (c) S. J. Cannon and S. Blechert, Angew. Chem Int. Ed., 2003, 42, 1900–1923.
- 18 (a) T. Yamamoto, H. Hasegawa, T. Hakogi and S. Katsumura, Org. Lett., 2006, 8, 5569–5572; (b) M. Lombardo, M. G. Capdevila, F. Pasi and C. Tombini, Org. Lett., 2006, 8, 3303–3305; (c) V. D. Chaudhari, K. S. A. Kumar and D. D. Dhavale, Org. Lett., 2005, 7, 5805–5807; (d) S. Torssell and P. Somfai, Org. Biomol. Chem., 2004, 2, 1643–1646; (e) A. N. Rai and A. Basu, Org. Lett., 2004, 6, 2861–2863; (f) O. V. Singh, D. J. Kampf and H. Han, Tetrahderon Lett., 2004, 45, 7239–7242.
- 19 T. M. Trnka and R. H. Grubbs, Acc. Chem. Res., 2001, 34, 18-29.
- 20 S. Raucher, Tetrahedron Lett., 1977, 44, 3909-3912.
- For a general review abaout asymetric sulfur ylide reaction see: (a) E. M. McGarrigle, E. L. Myers, O. Illa, M. A. Shaw, S. L. Riches and V. K. Aggarwal, *Chem. Rev.*, 2007, **107**, 5841–5883; (b) J. R. Fulton, V. K. Aggarwal and J. de Vicente, *Eur. J. Org. Chem.*, 2005, 1479–1492; (c) V. K. Aggarwal and C. L. Winn, *Acc. Chem. Res.*, 2004, **37**, 611–620; (d) V. K. Aggarwal and J. Richarson, *Chem. Commun.*, 2003, 2644– 2651; (e) A.-H. Li, L.-X. Dai and V. K. Aggarwal, *Chem. Rev.*, 1997, **97**, 2341–2372.
- 22 V. K. Aggarwal, G. Fang, C. G. Kokotos, J. Richardson and M. G. Unthank, *Tetrahedron*, 2006, 62, 11297–11303.
- 23 V. K. Aggarwal, I. Bae, H.-Y. Lee, J. Richardson and D. T. Williams, Angew. Chem. Int. Ed., 2003, 42, 3274–3278.
- 24 B. Olofsson and P. Somfai, J. Org. Chem., 2003, 68, 2514-2517.
- 25 (a) S. P. Bew, S. D. Bull, S. G. Davies, E. D. Savory and D. J. Waltkin, *Tetrahedron*, 2002, **58**, 9387–9401; (b) W. R. Roush and M. A. Adam, *J. Org. Chem.*, 1985, **50**, 3752–3757; (c) B. Bernet and A. Vasella, *Tetrahedron Lett.*, 1983, **24**, 5491–5494.
- 26 R. Julina, T. Herzig, B. Bernet and A. Vasella, *Helv. Chim. Acta*, 1986, 69, 368–373.